Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01278914|
Recruitment Status : Completed
First Posted : January 19, 2011
Last Update Posted : July 22, 2011
Determination of safety and toxicity of vaccination with mRNA transfected DC (based on blood samples, and adverse events).
Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Biological: Dendritic Cells (DC) prostate||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01278914
|Oslo university Hospital|